{"success":true,"data":{"pressRelease":{"id":"146888","rtpr_id":"nGNX1hYVW7-20260917","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock","author":"Globe Newswire","published_at":"2026-09-17T20:05:00.317Z","article_body":"IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq:\nBBNX) today announced the closing of its previously announced underwritten\npublic offering of 7,652,175 shares of its common stock at a price to the\npublic of $17.25 per share and, in lieu of shares of common stock to certain\ninvestors, pre-funded warrants to purchase 1,043,484 shares of common stock at\na purchase price of $17.2499 per share, which equals the public offering price\nper share of the common stock less the $0.0001 exercise price per share of\neach pre-funded warrant. In addition, the underwriters exercised their option\nin full and purchased 1,304,348 additional shares of common stock. Including\nthe option exercise, the aggregate gross proceeds from this offering were\n$172.5 million, before deducting underwriting discounts and commissions and\noffering expenses payable by Beta Bionics.\n\nBeta Bionics expects to use the net proceeds from this offering for general\ncorporate purposes, which may include costs associated with the\ncommercialization of Mint(™), including expansion of Beta Bionics’\nmanufacturing facilities, research and development and clinical development,\ninvestment in product enhancements, potential strategic opportunities and\nworking capital and operating expenses.\n\nJ.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted\nas the joint book-running managers for the offering.\n\nThe shares of common stock and pre-funded warrants described above were\noffered by Beta Bionics pursuant to a shelf registration statement on Form S-3\nthat was filed by Beta Bionics with the Securities and Exchange Commission\n(SEC) on February 24, 2026 and automatically became effective upon filing. A\nfinal prospectus supplement related to the offering has been filed with the\nSEC and is available on the SEC’s website located at http://www.sec.gov.\nCopies of the final prospectus supplement and the accompanying prospectus\nrelated to this offering may be obtained from J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717, or by email\nat prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com;\n(https://www.globenewswire.com/Tracker?data=Hwj66s5UeNCfnqgziBtslsdxKJmyyZpF5wYi2tLNZV444NjY-estZNC51sEEeBGkihVHyk5ZcauwNEM5K1697m6JHDzAsAgcG290QayjPdmTCtK8Bk0ZcqJQuha_goWJT-kOzD4525YdeQHV188WzD83DBTALBOr0cBPuX10u6qeb3_wZSskgnFhj4pUSi_KFRUjUCaNE4-oHReoHY2ISMpcP4xO4oBx7c8w-2moVMoPCO-LmVQpUaSPtkPECC_eHkAIYLXCmWcVyGRKdVlfFg==)\nor from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis,\nMinnesota 55401, Attention: Prospectus Department, by telephone at (800)\n747-3924, or by email at prospectus@psc.com;\n(https://www.globenewswire.com/Tracker?data=tUcoJIkvmTY-3wAjkTW2d1HILOEIG6Z1msn0hnKrtm0h1bkCmpCeXNzv-1KrpSnMvgp0nKPHPxaKt3crI0PynZKQlNC5G4WE-V3MzyTC2BI7W_moljcQPC-rw4gG6ZG2txrNDT7E7B_DDcbVQBkzXu0mzeaIOgD1s7savxMh3ZzJXtzVBt7ExeeXV9O7v-RaFH2jtKXamc_8EyCIWVqVj-324CH_AsaXub7OEOIUTkCoQ5fkSqg_1DqiXUyQtrl9rFFA-6abkswUekYasHnwz-IzQYDtax8slCJKuh4MfH6Ql4GyewdJsevGnEy9kmfJ)\nor from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90\nSouth 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at\n800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or\nfrom Leerink Partners LLC, Attention: Syndicate Department, 53 State Street,\n40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext.\n6105, or by email at syndicate@leerink.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Beta Bionics\nBeta Bionics, Inc. is a commercial-stage medical device company engaged in the\ndesign, development, and commercialization of innovative solutions to improve\nthe health and quality of life of insulin-requiring people with diabetes (PWD)\nby utilizing advanced adaptive closed-loop algorithms to simplify and improve\nthe treatment of their disease. The iLet Bionic Pancreas is the first\nFDA-cleared insulin delivery device that autonomously determines every insulin\ndose and offers the potential to substantially improve overall outcomes across\nbroad populations of PWD.\n\nCautionary Note on Forward-Looking Statements\nCertain statements in this press release are forward-looking statements that\ninvolve a number of risks and uncertainties. These statements may be\nidentified by introductory words such as “may,” “expects,” “goal,”\n“intend,” “will,” “would,” “subject to” or words of similar\nmeaning, or by the fact that they do not relate strictly to historical or\ncurrent facts. Such forward-looking statements include statements regarding\nBeta Bionics’ expectations with respect to the use of proceeds from the\noffering. For such statements, Beta Bionics claims the protection of the\nPrivate Securities Litigation Reform Act of 1995. Actual events or results may\ndiffer materially from Beta Bionics’ expectations. Factors that could cause\nactual results to differ materially from the forward-looking statements\ninclude, but are not limited to, those factors disclosed in Beta Bionics’\nfilings with the SEC, including its Annual Report on Form 10-K for the year\nended December 31, 2025, filed with the SEC on February 24, 2026, as updated\nby its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026,\nfiled with the SEC on July 29, 2026, and other filings that Beta Bionics may\nmake from time to time with the SEC. These forward-looking statements\nrepresent Beta Bionics’ judgment as of the time of this release. Beta\nBionics disclaims any intent or obligation to update these forward-looking\nstatements, other than as may be required under applicable law.\n\nInvestor Relations:\nBlake Beber\nHead of Investor Relations\nir@betabionics.com\n\nMedia and Public Relations:\nFelicia Sanborn\nVice President of Marketing\nmedia@betabionics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88df4d95-789c-467a-8481-f67e19e1adfa)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1hYVW7-20260917","title":"Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock","author":"Globe Newswire","ticker":"BBNX","created":"2026-09-17T20:05:00.317Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq:\nBBNX) today announced the closing of its previously announced underwritten\npublic offering of 7,652,175 shares of its common stock at a price to the\npublic of $17.25 per share and, in lieu of shares of common stock to certain\ninvestors, pre-funded warrants to purchase 1,043,484 shares of common stock at\na purchase price of $17.2499 per share, which equals the public offering price\nper share of the common stock less the $0.0001 exercise price per share of\neach pre-funded warrant. In addition, the underwriters exercised their option\nin full and purchased 1,304,348 additional shares of common stock. Including\nthe option exercise, the aggregate gross proceeds from this offering were\n$172.5 million, before deducting underwriting discounts and commissions and\noffering expenses payable by Beta Bionics.\n\nBeta Bionics expects to use the net proceeds from this offering for general\ncorporate purposes, which may include costs associated with the\ncommercialization of Mint(™), including expansion of Beta Bionics’\nmanufacturing facilities, research and development and clinical development,\ninvestment in product enhancements, potential strategic opportunities and\nworking capital and operating expenses.\n\nJ.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted\nas the joint book-running managers for the offering.\n\nThe shares of common stock and pre-funded warrants described above were\noffered by Beta Bionics pursuant to a shelf registration statement on Form S-3\nthat was filed by Beta Bionics with the Securities and Exchange Commission\n(SEC) on February 24, 2026 and automatically became effective upon filing. A\nfinal prospectus supplement related to the offering has been filed with the\nSEC and is available on the SEC’s website located at http://www.sec.gov.\nCopies of the final prospectus supplement and the accompanying prospectus\nrelated to this offering may be obtained from J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717, or by email\nat prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com;\n(https://www.globenewswire.com/Tracker?data=Hwj66s5UeNCfnqgziBtslsdxKJmyyZpF5wYi2tLNZV444NjY-estZNC51sEEeBGkihVHyk5ZcauwNEM5K1697m6JHDzAsAgcG290QayjPdmTCtK8Bk0ZcqJQuha_goWJT-kOzD4525YdeQHV188WzD83DBTALBOr0cBPuX10u6qeb3_wZSskgnFhj4pUSi_KFRUjUCaNE4-oHReoHY2ISMpcP4xO4oBx7c8w-2moVMoPCO-LmVQpUaSPtkPECC_eHkAIYLXCmWcVyGRKdVlfFg==)\nor from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis,\nMinnesota 55401, Attention: Prospectus Department, by telephone at (800)\n747-3924, or by email at prospectus@psc.com;\n(https://www.globenewswire.com/Tracker?data=tUcoJIkvmTY-3wAjkTW2d1HILOEIG6Z1msn0hnKrtm0h1bkCmpCeXNzv-1KrpSnMvgp0nKPHPxaKt3crI0PynZKQlNC5G4WE-V3MzyTC2BI7W_moljcQPC-rw4gG6ZG2txrNDT7E7B_DDcbVQBkzXu0mzeaIOgD1s7savxMh3ZzJXtzVBt7ExeeXV9O7v-RaFH2jtKXamc_8EyCIWVqVj-324CH_AsaXub7OEOIUTkCoQ5fkSqg_1DqiXUyQtrl9rFFA-6abkswUekYasHnwz-IzQYDtax8slCJKuh4MfH6Ql4GyewdJsevGnEy9kmfJ)\nor from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90\nSouth 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at\n800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or\nfrom Leerink Partners LLC, Attention: Syndicate Department, 53 State Street,\n40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext.\n6105, or by email at syndicate@leerink.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Beta Bionics\nBeta Bionics, Inc. is a commercial-stage medical device company engaged in the\ndesign, development, and commercialization of innovative solutions to improve\nthe health and quality of life of insulin-requiring people with diabetes (PWD)\nby utilizing advanced adaptive closed-loop algorithms to simplify and improve\nthe treatment of their disease. The iLet Bionic Pancreas is the first\nFDA-cleared insulin delivery device that autonomously determines every insulin\ndose and offers the potential to substantially improve overall outcomes across\nbroad populations of PWD.\n\nCautionary Note on Forward-Looking Statements\nCertain statements in this press release are forward-looking statements that\ninvolve a number of risks and uncertainties. These statements may be\nidentified by introductory words such as “may,” “expects,” “goal,”\n“intend,” “will,” “would,” “subject to” or words of similar\nmeaning, or by the fact that they do not relate strictly to historical or\ncurrent facts. Such forward-looking statements include statements regarding\nBeta Bionics’ expectations with respect to the use of proceeds from the\noffering. For such statements, Beta Bionics claims the protection of the\nPrivate Securities Litigation Reform Act of 1995. Actual events or results may\ndiffer materially from Beta Bionics’ expectations. Factors that could cause\nactual results to differ materially from the forward-looking statements\ninclude, but are not limited to, those factors disclosed in Beta Bionics’\nfilings with the SEC, including its Annual Report on Form 10-K for the year\nended December 31, 2025, filed with the SEC on February 24, 2026, as updated\nby its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026,\nfiled with the SEC on July 29, 2026, and other filings that Beta Bionics may\nmake from time to time with the SEC. These forward-looking statements\nrepresent Beta Bionics’ judgment as of the time of this release. Beta\nBionics disclaims any intent or obligation to update these forward-looking\nstatements, other than as may be required under applicable law.\n\nInvestor Relations:\nBlake Beber\nHead of Investor Relations\nir@betabionics.com\n\nMedia and Public Relations:\nFelicia Sanborn\nVice President of Marketing\nmedia@betabionics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88df4d95-789c-467a-8481-f67e19e1adfa)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-17T20:05:00.422843293Z","server_sent_at_ms":1789675500422},"received_at":"2026-09-17T20:05:00.476Z","source_url":null},"analysis":{"id":"135720","press_release_id":"146888","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["dilution of approximately 10.0 million share equivalents (8,956,523 shares plus 1,043,484 pre-funded warrants)","pre-funded warrants at a $0.0001 exercise price function economically as additional common shares","use of proceeds is broad 'general corporate purposes' rather than a specific capital need"],"eventType":"offering","narrative":"Beta Bionics closed its underwritten public offering, selling 7,652,175 shares at $17.25 per share plus pre-funded warrants on 1,043,484 shares, with the underwriters exercising their option in full for 1,304,348 additional shares.\n\nIncluding the option exercise, aggregate gross proceeds totaled $172.5 million before underwriting discounts and offering expenses, for roughly 10.0 million share equivalents in total.\n\nNet proceeds are earmarked for general corporate purposes, including commercialization of Mint, expansion of manufacturing facilities, R&D and clinical development, and working capital.\n\nJ.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted as joint book-running managers; the offering was made off a Form S-3 shelf registration filed February 24, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"Fully exercised $172.5M raise banks growth capital for the Mint commercialization while diluting holders by roughly 10 million share equivalents."},"keyFigures":{"dealValueUsd":172500000,"offeringPrice":17.25,"customDimensions":{"base_shares":7652175,"option_shares":1304348,"gross_proceeds":"$172.5 million","prefunded_warrants":1043484,"prefunded_warrant_price":17.2499,"total_share_equivalents":10000007,"prefunded_warrant_exercise_price":0.0001}},"namedEntities":{"people":[{"name":"Blake Beber","role":"Head of Investor Relations, Beta Bionics"},{"name":"Felicia Sanborn","role":"Vice President of Marketing, Beta Bionics"}],"products":["Mint","iLet Bionic Pancreas"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"joint book-running manager"},{"name":"Piper Sandler","relationship":"joint book-running manager"},{"name":"Wells Fargo Securities","relationship":"joint book-running manager"},{"name":"Leerink Partners","relationship":"joint book-running manager"}],"dollarAmounts":[{"amount":"$172.5 million","context":"aggregate gross proceeds from the offering, before underwriting discounts and expenses"},{"amount":"$17.25","context":"price to the public per share of common stock"},{"amount":"$17.2499","context":"purchase price per pre-funded warrant"},{"amount":"$0.0001","context":"exercise price per pre-funded warrant"}]},"materialImpact":{"score":3,"reasoning":"A $172.5 million equity raise (shares plus pre-funded warrants, option fully exercised) is a material capital event for a commercial-stage medtech and meaningfully dilutes holders, but it closed at the stated offering price with no disclosed discount and no prior close given, so it is not a market-moving binary event."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":30,"audienceRelevance":30,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small/mid-cap medtech","eventGravity":"$172.5M equity offering closed with full option exercise","sectorWeight":"medical devices","issuerAuthored":true,"dilutionSignificance":"~10M share equivalents issued at $17.25; no prior close disclosed"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"neutral","material_impact_score":3,"narrative":"Beta Bionics closed its underwritten public offering, selling 7,652,175 shares at $17.25 per share plus pre-funded warrants on 1,043,484 shares, with the underwriters exercising their option in full for 1,304,348 additional shares.\n\nIncluding the option exercise, aggregate gross proceeds totaled $172.5 million before underwriting discounts and offering expenses, for roughly 10.0 million share equivalents in total.\n\nNet proceeds are earmarked for general corporate purposes, including commercialization of Mint, expansion of manufacturing facilities, R&D and clinical development, and working capital.\n\nJ.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted as joint book-running managers; the offering was made off a Form S-3 shelf registration filed February 24, 2026.","key_figures":{"dealValueUsd":172500000,"offeringPrice":17.25,"customDimensions":{"base_shares":7652175,"option_shares":1304348,"gross_proceeds":"$172.5 million","prefunded_warrants":1043484,"prefunded_warrant_price":17.2499,"total_share_equivalents":10000007,"prefunded_warrant_exercise_price":0.0001}},"named_entities":{"people":[{"name":"Blake Beber","role":"Head of Investor Relations, Beta Bionics"},{"name":"Felicia Sanborn","role":"Vice President of Marketing, Beta Bionics"}],"products":["Mint","iLet Bionic Pancreas"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"joint book-running manager"},{"name":"Piper Sandler","relationship":"joint book-running manager"},{"name":"Wells Fargo Securities","relationship":"joint book-running manager"},{"name":"Leerink Partners","relationship":"joint book-running manager"}],"dollarAmounts":[{"amount":"$172.5 million","context":"aggregate gross proceeds from the offering, before underwriting discounts and expenses"},{"amount":"$17.25","context":"price to the public per share of common stock"},{"amount":"$17.2499","context":"purchase price per pre-funded warrant"},{"amount":"$0.0001","context":"exercise price per pre-funded warrant"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-17T20:05:42.797Z","global_importance":30,"audience_relevance":30,"importance_components":{"tickerTier":"small/mid-cap medtech","eventGravity":"$172.5M equity offering closed with full option exercise","sectorWeight":"medical devices","issuerAuthored":true,"dilutionSignificance":"~10M share equivalents issued at $17.25; no prior close disclosed"}},"durationMs":42238,"modelName":"glm-5.3-flash"}}